Mirati Therapeutics Gets $65M In Deal With China’s Zai Lab

San Diego-based oncology therapeutics developer Mirati Therapeutics said this morning that it has received $65M in an upfront payment, as part of a deal with Chinese company Zai Lab. According to the to companies,t he two have entered into a collaboration to develop and commercialize Mirati's Adagrasib in Greater China. Mirati will receive $65M upfront, with up to approximately $273M in potential milestone payments and royalties. Charles M. Baum, M.D., Ph.D., is President and CEO of Mirati Therapeutics. The company's cancer treatment is aimed at treating patients with the KRASG12C mutation.